Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CRSP vs LGND: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LGND Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 6–4 Matrix Metrics)

LGND Overall Winner 6-Pillar Tally: CRSP 1 – 5 LGND Matrix Metrics: CRSP 4 – 6 LGND

As of Nov 16, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRSP carries a Unified Composite Score of 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas LGND carries 42.6/100 (HOLD) at $304.93 (25.8x Forward P/E, 14.4% operating margin).

  • Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. LGND 42.6/100 HOLD), LGND captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.4% vs. -2058.6% operating margin) and revenue trajectory (-31.8% vs. +1325.1% YoY).
  • Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CRSP vs LGND
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
TTM Revenue $25M
Forward P/E 23.4x
Beta / 30D Vol 1.85β · 60% Vol
Unified Composite Score
44.7 / 100 HOLD
Tech 25.0 Fund 52.0 Flow 68.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.6%), weak momentum, RSI 30
RSI-14: 29.6 · SMA20: $48.84 · SMA50: $51.79
LGND NASDAQ Head-to-Head Winner
Ligand Pharmaceuticals Inc.
Pharmaceutical Preparations
$304.93
-1.25% 1D
Market Cap $6.3B
TTM Revenue $254M
Forward P/E 25.8x
Beta / 30D Vol 0.99β · 38% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 44.0 Fund 47.0 Flow 63.0 Mom 31.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 48
RSI-14: 47.6 · SMA20: $311.42 · SMA50: $302.10

6-Pillar Scorecard Institutional Category Breakdown (CRSP 1 – 5 LGND)

Columns: Metric · CRSP · LGND
1. Valuation Multiples CRSP
Forward P/E 23.4x 25.8x
Trailing P/E 23.4x 127.0x
PEG Ratio N/M 1.53x
EV / Revenue N/M 29.3x
2. Growth & Scale LGND
Revenue Growth (YoY) +1325.1% -31.8%
Earnings Growth (YoY) +0.0% +825.0%
TTM Revenue (USD) $25M $254M
Market Cap $4.1B $6.3B
3. Profitability & Quality LGND
Gross Margin N/A 86.1%
Operating Margin -2058.6% 14.4%
Net Profit Margin 0.0% 20.3%
Return on Equity (ROE) -25.6% 5.4%
4. Balance Sheet & Cash Flow LGND
Cash Generation (TTM) -$378M $57M
Cash Flow Margin N/A 22.6%
Net Cash / Leverage $588M Net Debt (0.47x D/E) $1.10B Net Debt (1.20x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LGND
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 97.8% (52nd %ile) 37.9% (8th %ile)
Put/Call OI Skew 0.65x (Call-Skewed) 0.42x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat LGND
OpEx & R&D Intensity N/A 71.7% of Rev ($182M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CRSP (4) vs LGND (6)
Institutional Metric CRSP LGND Criterion Row Edge
Market Capitalization
Scale
$4.1B $6.3B Larger Scale LGND
Trailing P/E Ratio
Valuation
23.4x 127.0x Lower Multiple CRSP
Forward P/E Ratio
Valuation
23.4x 25.8x Lower Multiple CRSP
Revenue Growth (YoY)
Growth
+1325.1% -31.8% Higher Growth CRSP
Operating Margin (TTM)
Profitability
-2058.6% 14.4% Higher Margin LGND
Net Profit Margin
Profitability
0.0% 20.3% Higher Margin LGND
Return on Equity (ROE)
Capital Efficiency
-25.6% 5.4% Higher ROE LGND
52-Week Range Position
Momentum
1% ($40–$63) 86% ($176–$327) Stronger Trend LGND
Beta / 30D Volatility
Risk Regime
1.85β · 60% Vol 0.99β · 38% Vol Lower Realized Risk LGND
Unified Institutional Score
Composite Signal
44.7 / 100 (HOLD) 42.6 / 100 (HOLD) Higher Composite CRSP
Trailing 12M Revenue (USD)
Operating Scale
$25M $254M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 86.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 1.53x PEG · 29.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$378M ($588M Net Debt (0.47x D/E)) $57M ($1.10B Net Debt (1.20x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LGND +20.72 pp
CRSP: -17.54% · LGND: +3.18%
3M Horizon LGND +29.36 pp
CRSP: -23.33% · LGND: +6.03%
6M Horizon LGND +63.05 pp
CRSP: -16.37% · LGND: +46.68%
1Y Horizon LGND +72.04 pp
CRSP: -20.54% · LGND: +51.5%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CRSP Revenue LGND Revenue CRSP Op. Margin LGND Op. Margin Margin Leader
FY2018 $0M $250M -5087.8% 65.1% LGND
FY2019 $290M $120M 16.1% 671.0% LGND
FY2020 $0M $160M -49295.5% 22.9% LGND
FY2021 $910M $240M 40.8% 43.0% LGND
FY2022 $0M $200M -56190.4% 1.5% LGND
FY2023 $370M $130M -60.0% 9.1% LGND
FY2024 $40M $170M -1250.4% -13.5% LGND
FY2025 $0M $270M -18933.6% 15.3% LGND

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CRSP BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 97.8%
IV Percentile 52nd %ile
Put/Call OI Skew 0.65x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CRSP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LGND CONSOLIDATION
98d in phase · OBV NEUTRAL
Current IV 37.9%
IV Percentile 8th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LGND Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CRSP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.1B market capitalization and -2058.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LGND Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and 14.4% operating margin.
OpEx & R&D Reinvestment 71.7% of Rev ($182M)
90D Engineering Disclosures 0 Published

Investor FAQ CRSP vs LGND Key Questions & Quantitative Answers

As of Nov 16, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over CRISPR Therapeutics AG (CRSP) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CRSP carries a Unified Composite Score of 44.7/100 (HOLD) at $40.61 (23.4x Forward P/E, -2058.6% operating margin), whereas LGND carries 42.6/100 (HOLD) at $304.93 (25.8x Forward P/E, 14.4% operating margin). Composite vs. Pillar Nuance: While CRSP currently prints a higher short-term Unified Composite Score (44.7/100 HOLD vs. LGND 42.6/100 HOLD), LGND captures the overall institutional head-to-head verdict (6–4 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (14.4% vs. -2058.6% operating margin) and revenue trajectory (-31.8% vs. +1325.1% YoY). Technical & Structure Timing Caution: CRSP is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.6); meanwhile LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LGND leads the Growth & Scale pillar: CRSP posts +1325.1% YoY revenue growth and +0.0% YoY earnings growth on $25M TTM revenue (N/A gross margin, -2058.6% operating margin), compared with LGND at -31.8% YoY revenue growth and +825.0% YoY earnings growth on $254M TTM revenue (86.1% gross margin, 14.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CRSP cumulative revenue shifted -86.2% while LGND shifted +8.0%. In operating R&D and SG&A reinvestment, CRSP deploys N/A (0 90-day corporate R&D disclosures) versus 71.7% of Rev ($182M) (0 disclosures) for LGND.

CRSP screens cheaper on headline valuation multiples. CRSP trades at 23.4x Forward P/E, 23.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LGND trades at 25.8x Forward P/E, 127.0x Trailing P/E, 1.53x PEG, and 29.3x EV/Revenue (22.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CRSP (-25.6% ROE) versus LGND (5.4% ROE) capital efficiency.

In options market volatility and institutional positioning, CRSP carries 97.8% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.65x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.85β · 60% Vol realized risk). By comparison, LGND carries 37.9% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.99β · 38% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.